Xencor
The Executive Director, Biostatistics leads and manages all biostatistics activities across Phase I through Phase III clinical programs in Oncology and Autoimmune diseases, ensuring scientific rigor and regulatory compliance. This hybrid role involves providing strategic oversight for statistical analyses, directing the design of clinical trials, and managing external vendor relationships including CROs. The position also entails mentoring a high-performing team, establishing biostatistics standards, and representing the function as a scientific resource across development programs.
Headquarters
Pasadena, California, United States
Company Size
201-500 employees
Founded
1997
Xencor is a clinical-stage biopharmaceutical company that designs engineered proteins to create novel biologic medicines. Using proprietary protein-design platforms (including XmAb Fc engineering and cytokine/antibody engineering), Xencor builds next‑generation monoclonal antibodies, bispecifics and cytokine therapeutics with improved potency, half‑life and safety. The company advances an internal pipeline across oncology and immune‑mediated diseases while partnering with other biopharma organizations to discover and develop therapeutics. Xencor emphasizes rational protein design and translational science to deliver differentiated medicines to patients.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Xencor.
38% above the average for this role